Stock comparison
MannKind
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MNKD
MannKind
Market cap
$1.04B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MNKD | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 72B | RMD |
| Benjamin Graham | 23F | 75B | RMD |
| Philip Fisher | 59C | 75B | RMD |
| Peter Lynch | 60C | 58C | MNKD |
| Joel Greenblatt | 40D | 47D | RMD |
| Charlie Munger | 48D | 69B | RMD |
| Terry Smith | 52D | 73B | RMD |
Side-by-side metrics
| Metric | MNKD | RMD |
|---|---|---|
| Market cap | $1.04B | $30.18B |
| P/E (TTM) | - | 19.6x |
| EV/EBIT | 36.6x | 17.1x |
| ROIC (TTM) | 1.8% | 19.63% |
| Gross margin | 75.96% | 61.69% |
| Net margin | -6.63% | 27.44% |
| Revenue CAGR 5y | 46.65% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MNKD leads on
- P/E (TTM)-vs 19.6x+145%
- Debt / Equity-vs 0.1x+102%
- Revenue CAGR 5y46.65%vs 12.64%+73%
- Gross margin75.96%vs 61.69%+19%
RMD leads on
- Net margin27.44%vs -6.63%+124%
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $1.04B+97%
- ROIC (TTM)19.63%vs 1.8%+91%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.